U.S. Anti-vascular Endothelial Growth Factor Therapeutics Market Size & Outlook
U.S. anti-vascular endothelial growth factor therapeutics market, 2018-2030 (US$M)
Related Markets
U.S. anti-vascular endothelial growth factor therapeutics market highlights
- The U.S. anti-vascular endothelial growth factor therapeutics market generated a revenue of USD 9,033.0 million in 2024 and is expected to reach USD 8,582.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of -1.3% from 2025 to 2030.
- In terms of segment, eylea was the largest revenue generating product in 2024.
- Vabysmo is the most lucrative product segment registering the fastest growth during the forecast period.
Anti-vascular endothelial growth factor therapeutics market data book summary
| Market revenue in 2024 | USD 9,033.0 million |
| Market revenue in 2030 | USD 8,582.4 million |
| Growth rate | -1.3% (CAGR from 2025 to 2030) |
| Largest segment | Eylea |
| Fastest growing segment | Vabysmo |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
| Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 62.1% of the global anti-vascular endothelial growth factor therapeutics market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. anti-vascular endothelial growth factor therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 484.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Anti-Vascular Endothelial Growth Factor Therapeutics Market Scope
Anti-Vascular Endothelial Growth Factor Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. anti-vascular endothelial growth factor therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 59.42% in 2024. Horizon Databook has segmented the U.S. anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
In the U.S., there are around 11 million people affected by AMD, out of which, 10% of cases accounted for wet AMD. This number is expected to increase twofold by 2050. In addition, around 90% of diagnosed cases account for dry AMD. This significant disease burden shows the promising growth of the market.
The market is expected to witness lucrative growth over the forecast period, owing to research initiatives, product launches, and a robust product pipeline. For instance, in February 2021, Outlook Therapeutics, Inc. announced the completion of phase 3 clinical trial of its potential candidate, ONS-5010/LYTENAVA on a range of indications, including Diabetic Macular Edema (DME), wet AMD, and Branch Retinal Vein Occlusion (BRVO).
In January 2020, Exonate entered into a research collaboration agreement with Johnson & Johnson Services, Inc. for the development of anti-VEGF drug-class based eye drops for the indication of DME and wet AMD. The launch of effective novel treatments such as Novartis AG’s proprietary Beovu may contribute to growth of market.
Reasons to subscribe to U.S. anti-vascular endothelial growth factor therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. anti-vascular endothelial growth factor therapeutics market databook
-
Our clientele includes a mix of anti-vascular endothelial growth factor therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. anti-vascular endothelial growth factor therapeutics market size, by product, 2018-2030 (US$M)
U.S. Anti-Vascular Endothelial Growth Factor Therapeutics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
